Capricor Therapeutics Inc — Quarterly Financial Statistics (NASDAQ:CAPR) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics Dividends

Quarterly Annual

Cash from operating activities -11.64 M-14.8 M-6.43 M-20.12 M-19.69 M -61.04 M Cash from investing activities 2 M-123.38 M23.89 M14.55 M15.95 M -68.99 M Cash from financing activities 67.33 M81.09 M50.35 K19.58 K6 950 81.16 M Free cash flow -11.65 M-15.29 M-7.33 M-20.41 M-19.74 M -62.77 M

Nouvelles

Oppenheimer maintient sa note Surperformance sur l’action Capricor, avec un objectif de 54€

Oppenheimer reiterates Outperform rating on Capricor stock, maintains $54 target

CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February

Capricor to submit HOPE-3 data to FDA for DMD therapy review

Cantor Fitzgerald réitère sa notation pour l’action Capricor Therapeutics

Capricor Therapeutics stock rating reiterated by Cantor Fitzgerald

Cantor Fitzgerald reiterates Overweight rating on Capricor stock

Capricor Therapeutics Stock: A High Risk/High Reward Name (NASDAQ:CAPR)

Biotech Stocks' Dark Winter Is Over. What That Means For Investors.

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript

Piper Sandler maintient sa notation pour Capricor et la désigne comme meilleur choix pour 2026

Piper Sandler reiterates Capricor stock rating, names it 2026 top pick